氨氯地平对高血压伴心衰患者左心室功能的影响被引量：2

导出

摘要目的:探讨氨氯地平治疗高血压伴心衰的疗效,及其对左心室功能的影响。方法:选择本院2011年1月～2012年1月收治的高血压伴左心衰竭患者68例在常规吸氧、强心和利尿剂治疗的基础上接受氨氯地平治疗(观察组),另选择同期仅接受常规治疗的40例患者作对照。观察并比较2组患者治疗前后血压、心率,及对左心室功能的影响。结果:2组患者治疗前后SBP、DBP和心率均有所改善(P<0.05),且观察组的下降幅度显著高于对照组(P<0.05),且治疗后观察组在LVEF、LVEDD、LVESD、LVPER和LVMI等方面显著好于对照组(P<0.05)。结论:在常规治疗基础上氨氯地平能够快速降低患者血压,且对左心室功能具有较好的改善作用,值得临床推广。

作者昂虎宋文娟

机构地区云南省建水县曲江中心卫生院云南省昆明市第三人民医院

出处《中国伤残医学》 2013年第3期103-104,共2页 Chinese Journal of Trauma and Disability Medicine

关键词高血压心力衰竭氨氯地平左心室功能

分类号 R541 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1吴学思.高血压伴慢性心力衰竭的诊治进展[C].第3届东北高血压及相关疾病论坛论文集,2011,69-72.
2段朝龙.左旋氨氯地平联合依那普利对高血压合并心衰患者的临床疗效观察[J].中国医药导报,2012,9(27):80-81. 被引量：16
3Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology (ESC). J Hypertens, 2007, 25(6):1105- 1187.
4陆再英,钟南山,主编.内科学[M].第7版.北京:人民卫生出版社,2008:778-779.
5刘志勇,刘玉洁,耿庆国,吕建国,张金莲,丛洪良,孙根义.老年高血压左心室肥厚患者左心室重构和冠状动脉病变分析[J].中华老年心脑血管病杂志,2011,13(7):608-610. 被引量：8
6王文,马丽媛,刘明波,邓卿,张宇清,李卫,朱鼎良,林曙光,黄峻,刘力生.初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高血压患者血压控制率影响的阶段报告[J].中华心血管病杂志,2009,37(8):701-707. 被引量：89
7刘世宇.硝普钠治疗高血压急性左心衰80例疗效观察[J].中国现代药物应用,2011,5(9):69-70. 被引量：4
8彭峰,林金秀,吴雅芳,林建珍,杨霞.氨氯地平和硫氮革酮缓释片联合治疗对高血压病患者血压和动脉弹性功能及尿蛋白的影响[J].中华心血管病杂志,2007,35(9):830-832. 被引量：7

二级参考文献36

1张雪花.多巴胺、硝普钠联合治疗顽固性心衰疗效观察[J].陕西医学杂志,2008,37(7):901-902. 被引量：9
2卫生部心血管病防治研究中心.中国心血管病报告2006.北京:中国大百科全书出版社,2007.
3Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long- term placebo-controlled trial in Chinese hypertensive patients. J Hypertens, 2005,23 : 2157-2572.
4Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363:2022-2031.
5Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet ,2003,361 : 1149-1158.
6Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press ,2007,16 : 13-19.
7Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers : a quantitative overview. Hypertension, 2007,50 : 181 - 188.
8Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes : a post-hoc analysis of The Incipient to Overt: Angiotensin Ⅱ Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res,2008,31:657-664.
9Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase Ⅲ, 12-week, muhicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed- dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage Ⅱ hypertension. Clin Ther, 2007,29 : 2667 -2676.
10Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension : focus on amlodipine/olmesartan combination. Drugs Today (Barc) ,2008,44:443-453.